Blog
RSS FeedPosted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis
11 April 2019 - Document open to public comment until 1 May 2019. ...
Posted by Michael Wonder on 09 Apr 2019
Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy
9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 17 Mar 2019
On the use of list prices in drug pricing research
14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...
Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...
Posted by Michael Wonder on 25 Sep 2018
ICER releases draft evidence report on biologic treatments for asthma
24 September 2018 - Public comment period now open until 22 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 02 Aug 2018
Institute for Clinical and Economic Review lists potential options for assessments in 2019
2 August 2018 - ICER will select 2019 topics from a wide range of treatments, medical devices, and IT-based interventions. ...
Posted by Michael Wonder on 20 Jul 2018
ICER releases draft evidence report on inotersen and patisiran for hereditary transthyretin amyloidosis
20 July 2018 - Public comment period now open until 17 August; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 12 Jul 2018
ICER releases draft evidence report on anti-androgen therapies for non-metastatic castration-resistant prostate cancer
12 July 2018 - Public comment period now open until 9 August; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 27 Apr 2018
ICER releases draft condition update report on treatments for plaque psoriasis
27 April 2018 - Public comment period now open until 25 May; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 16 Apr 2018
ICER's final report on emicizumab shows new treatment improves health while lowering costs for certain people with haemophilia A
16 April 2018 - Report also highlights need for future pricing of haemophilia treatments that allows for "shared savings" between innovators ...
Posted by Michael Wonder on 12 Apr 2018
ICER releases draft evidence report on CGRP inhibitors for migraine prevention
11 April 2018 - Public comment period now open until 8 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 10 Apr 2018
ICER publishes guidance on improving the development and use of real world evidence for drug coverage and formulary decisions
10 April 2018 - The ICER, in collaboration with the Office of Health Economics, has released two new white papers to ...
Posted by Michael Wonder on 30 Mar 2018
ICER announces new program to make available draft executable economic models during drug assessment review process
30 March 2018 - Pilot program will allow more extensive evaluation of draft economic models used in ICER's reports. ...
Posted by Michael Wonder on 16 Mar 2018
ICER releases draft evidence report on CFTR modulator therapies for cystic fibrosis
15 March 2018 - Public comment period now open until 12 April; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 26 Jan 2018
Institute for Clinical and Economic Review releases draft evidence report on emicizumab for haemophilia A
26 January 2018 - Public comment period now open until 23 February 23; requests to make oral comment during public meeting ...